Blood markers for early complications after donor stem cell transplant
Part of Heart & circulation, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at blood tests before and after a donor stem cell transplant to see if certain markers can predict early complications. If you are planning this type of transplant, your participation could help doctors better manage side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 65 years old or younger.
- You must be scheduled to receive a stem cell transplant from a donor (called an allogeneic transplant).
- Your heart and kidneys must be working normally before the transplant.
- You cannot have severe kidney or heart problems, a history of mental illness, or be unwilling to sign the consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for proteins or markers in your blood that could help predict a condition called chronic graft-versus-host disease (cGVHD), a common complication after a stem cell transplant from a donor. By joining, you may help doctors detect and treat this condition earlier.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
This trial looks for proteins in the blood that could help detect transplant-related blood vessel damage (called TMA) earlier, so doctors can treat it faster. It involves patients who have had a stem cell transplant from a donor.
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Hear when a new Stem Cell Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.